| Drug General Information |
| Drug ID |
D0T9ZL
|
| Former ID |
DIB019121
|
| Drug Name |
chelerythrine
|
| Synonyms |
broussonpapyrine; cheleritrine; chelerythrine hydroxide; toddalin
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C21H18NO4+
|
| InChI |
InChI=1S/C21H18NO4/c1-22-10-16-13(6-7-17(23-2)21(16)24-3)14-5-4-12-8-18-19(26-11-25-18)9-15(12)20(14)22/h4-10H,11H2,1-3H3/q+1
|
| InChIKey |
LLEJIEBFSOEYIV-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14372, 598373, 4963886, 6014120, 8151752, 11110929, 11407741, 11446024, 12159009, 14851851, 24263000, 26755665, 26755666, 29203936, 29221860, 47662496, 47736687, 48185172, 50064705, 50110986, 50110987, 50110988, 53787519, 56412814, 57321405, 76839505, 85787754, 90340614, 92309974, 99300886, 104301361, 117695704, 117695715, 123092434, 124749565, 124879604, 124879605, 124879606, 124879607, 124879608, 125823454, 128505041, 135030853, 137185564, 137548913, 142652070, 160658093, 162188775, 162220823, 162969537
|
| Target and Pathway |
| Target(s) |
P2X purinoceptor 7 |
Target Info |
Modulator (allosteric modulator) |
[1]
|
|---|
| mRNA of PKC-epsilon |
Target Info |
Inhibitor |
[2]
|
| Protein kinase A |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Vascular smooth muscle contraction
|
|
Tight junction
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
Inflammatory mediator regulation of TRP channels
|
|
Type II diabetes mellitus
|
|
MicroRNAs in cancer
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathway
|
|
Alzheimer disease-amyloid secretase pathway
|
|
Angiogenesis
|
|
Apoptosis signaling pathway
|
|
EGF receptor signaling pathway
|
|
Endothelin signaling pathway
|
|
FGF signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
VEGF signaling pathway
|
|
Wnt signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
Histamine H1 receptor mediated signaling pathway
|
|
Oxytocin receptor mediated signaling pathway
|
|
Thyrotropin-releasing hormone receptor signaling pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Endothelins
|
|
LPA receptor mediated events
|
|
TCR signaling in naï
|
|
LPA4-mediated signaling events
|
|
CDC42 signaling events
|
|
TCR signaling in naï
|
|
Thromboxane A2 receptor signaling
|
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
IL2-mediated signaling events
|
|
PDGFR-beta signaling pathway
|
|
IL8- and CXCR1-mediated signaling events
|
|
Regulation of Ras family activation
|
|
Downstream signaling in naï
|
|
Reactome
|
The NLRP3 inflammasomeR-HSA-114508:Effects of PIP2 hydrolysis
|
|
DAG and IP3 signaling
|
|
Role of phospholipids in phagocytosis
|
|
G alpha (z) signalling events
|
|
WikiPathways
|
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathwaysWP666:Hypothetical Network for Drug Addiction
|
|
Calcium Regulation in the Cardiac Cell
|
|
Wnt Signaling Pathway
|
|
Wnt Signaling Pathway and Pluripotency
|
|
G Protein Signaling Pathways
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Oncostatin M Signaling Pathway
|
|
miRs in Muscle Cell Differentiation
|
|
GPCR downstream signaling
|
|
Effects of PIP2 hydrolysis
|
|
Physiological and Pathological Hypertrophy of the Heart
|
| References |
| REF 1 | Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor. Br J Pharmacol. 2004 Jul;142(6):1015-9. Epub 2004 Jun 21. |
|---|
| REF 2 | Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. Epub 2007 Dec 11.A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
|---|
